Acetylcysteine/bromelain - Mucpharm
Alternative Names: BromAc; Bromelain/acetylcysteine - MucopharmLatest Information Update: 20 Sep 2022
Price :
$50 *
At a glance
- Originator Mucpharm
- Class Anti-inflammatories; Antibronchitics; Antidotes; Antineoplastics; Cysteine endopeptidases; Expectorants; Mucolytics; Reducing agents; Skin disorder therapies; Small molecules; Sulfur amino acids
- Mechanism of Action Antioxidants; Free radical inhibitors; Glutamate receptor modulators; Mucin inhibitors; Peptide hydrolase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections; Respiration disorders
- Clinical Phase Unknown Peritoneal cancer
- Preclinical Adenocarcinoma
Most Recent Events
- 25 Aug 2022 Mucpharm completes a phase I trial in healthy volunteers for COVID-19 infections (In adults, In the elderly, In volunteers) in Australia (Inhalation, Liquid) (NCT05220605)
- 08 Feb 2022 Clinical trials in Peritoneal cancer (Intraperitoneal) prior to February 2022 (Mucpharm website, February 2022)
- 08 Feb 2022 Phase-I clinical trials in Respiration disorders (Inhalation) (Mucpharm website, February 2022)